Published in Psychiatry Res on February 01, 1993
Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia | NCT00169039
Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacol Bull (2011) 0.82
Predictors and markers of clozapine response. Psychopharmacology (Berl) (2005) 0.82
A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagn (2015) 0.80
Blood biogenic amines during clozapine treatment of early-onset schizophrenia. J Neural Transm (Vienna) (1997) 0.75
Longitudinal analyses of prenatal and postnatal lead exposure and early cognitive development. N Engl J Med (1987) 7.13
Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry (1999) 5.29
One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry (1994) 5.29
The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry (1965) 5.09
Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry (1993) 4.98
Biogenic amines and emotion. Science (1967) 3.49
Low-level lead exposure and children's cognitive function in the preschool years. Pediatrics (1991) 3.24
A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA (1997) 2.80
Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry (2000) 2.70
The Yugoslavia Prospective Lead Study: contributions of prenatal and postnatal lead exposure to early intelligence. Neurotoxicol Teratol (2001) 2.25
Side effects and the "blindability" of clinical drug trials. Am J Psychiatry (1992) 2.13
The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry (1998) 2.13
Risperidone: a novel antipsychotic medication. Hosp Community Psychiatry (1994) 2.03
Metabolism of normetanephrine-H3 in rat brain--identification of conjugated 3-methoxy-4-hydrophenylglycol as the major metabolite. Biochem Pharmacol (1968) 1.86
Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry Suppl (1998) 1.73
Random regression models: a comprehensive approach to the analysis of longitudinal psychiatric data. Psychopharmacol Bull (1988) 1.66
Social functioning in depression: a review. J Clin Psychiatry (2000) 1.62
Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. Am J Psychiatry (2000) 1.61
The effects of psychoactive drugs on norepinephrine-3-H metabolism in brain. Biochem Pharmacol (1967) 1.54
Gender differences in chronic major and double depression. J Affect Disord (2000) 1.53
Low-level lead exposure, social class, and infant development. Neurotoxicol Teratol (1989) 1.51
Differential actions of chlordiazepoxide and oxazepam on hostility. Arch Gen Psychiatry (1968) 1.50
Results, charges, and benefits of intensive care for critically ill patients: update 1983. Crit Care Med (1984) 1.46
Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. J Affect Disord (1999) 1.45
ECT, research, and professional ambivalence. Am J Psychiatry (1998) 1.43
Dilative cardiomyopathy leading to congestive heart failure in a male squirrel monkey (Saimiri sciureus). J Med Primatol (2000) 1.42
Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol Psychiatry (2010) 1.42
Geriatric psychopharmacology. Annu Rev Med (1985) 1.41
Serotonin transporter polymorphism, memory and hippocampal volume in the elderly: association and interaction with cortisol. Mol Psychiatry (2007) 1.40
Psychopharmacological screening criteria. APA Committee on Research on Psychiatric Treatments. J Clin Psychiatry (1992) 1.39
Suicidal behavior in bipolar mood disorder: clinical characteristics of attempters and nonattempters. J Affect Disord (2000) 1.36
Environmental correlates of infant blood lead levels in Boston. Environ Res (1985) 1.35
Correlates of low-level lead exposure in urban children at 2 years of age. Pediatrics (1986) 1.35
Early sensory-motor development and prenatal exposure to lead. Neurobehav Toxicol Teratol (1985) 1.34
A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res (1985) 1.33
An epidemiological assessment of immunization programme participation in the Philippines. Int J Epidemiol (1985) 1.32
Early life stress and inherited variation in monkey hippocampal volumes. Arch Gen Psychiatry (2001) 1.29
Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. J Psychiatr Res (2001) 1.26
Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry (1999) 1.21
Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol (2001) 1.21
Low-level lead exposure and infant development in the first year. Neurobehav Toxicol Teratol (1986) 1.19
Medication and psychotherapy in the treatment of bulimia nervosa. Am J Psychiatry (1997) 1.19
Stress-induced changes in primate prefrontal profiles of gene expression. Mol Psychiatry (2007) 1.18
Corticosteroids and cognition. J Psychiatr Res (2001) 1.18
Benzodiazepines in depressive disorders. Arch Gen Psychiatry (1978) 1.15
24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch Gen Psychiatry (2000) 1.15
Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry (2000) 1.15
The catecholamine hypothesis of affective disorders: a review of supporting evidence. 1965. J Neuropsychiatry Clin Neurosci (1995) 1.14
Psychological versus pharmacological treatments of bulimia nervosa: predictors and processes of change. J Consult Clin Psychol (1999) 1.14
Depression in the elderly. I. Relationship between depression, psychologic defense mechanisms and physical illness. J Am Geriatr Soc (1978) 1.11
Lead, IQ and social class. Int J Epidemiol (1989) 1.08
Nocturnal sleep apnea/hypopnea is associated with lower memory performance in APOE epsilon4 carriers. Neurology (2005) 1.07
The current status of biological criteria for classifying the depressive disorders and predicting responses to treatment. Psychopharmacol Bull (1974) 1.06
The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. J Clin Psychiatry (1998) 1.05
Clozapine: benefits and risks. Hosp Community Psychiatry (1990) 1.05
Stress-level cortisol treatment impairs inhibitory control of behavior in monkeys. J Neurosci (2000) 1.03
Relationships between brain CT scan findings and cortisol in psychotic and nonpsychotic depressed patients. Biol Psychiatry (1989) 1.01
The APA Task Force report on benzodiazepine dependence, toxicity, and abuse. Am J Psychiatry (1991) 1.01
Nicotine patch and paroxetine for smoking cessation. J Consult Clin Psychol (2000) 1.01
Heroin use as an attempt to cope: clinical observations. Am J Psychiatry (1974) 1.00
A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment--Geriatric (SCAG). J Am Geriatr Soc (1974) 0.99
Chlordiazepoxide-induced hostility in a small group setting. Arch Gen Psychiatry (1974) 0.99
Norepinephrine metabolites as biochemical criteria for classifying depressive disorders and predicting responses to treatment: preliminary findings. Am J Psychiatry (1973) 0.99
Gender differences in presentation of chronic major depression. Psychopharmacol Bull (1995) 0.98
Cortisol activity and cognitive changes in psychotic major depression. Am J Psychiatry (2001) 0.97
Diurnal variation of plasma cortisol and homovanillic acid in healthy subjects. Psychoneuroendocrinology (1996) 0.97
Normetanephrine excretion and affective state in depressed patients treated with imipramine. Am J Psychiatry (1966) 0.97
Amphetamine withdrawal: affective state, sleep patterns, and MHPG excretion. Am J Psychiatry (1972) 0.96
The dexamethasone suppression test: identification of subtypes of depression. Am J Psychiatry (1983) 0.95
Postnatal experiences and genetic effects on squirrel monkey social affinities and emotional distress. Horm Behav (1999) 0.95
Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based Nightcap evaluation during drug administration and withdrawal. J Clin Psychiatry (2001) 0.94
Long-Term use of quetiapine in elderly patients with psychotic disorders. Clin Ther (2000) 0.93
The effects of delta-9-tetrahydrocannabinol on the metabolism of norepinephrine in rat brain. Psychopharmacologia (1971) 0.93
Amphetamine withdrawal: effects on threshold of intracranial reinforcement. Psychopharmacology (Berl) (1981) 0.92
ECT and ethical psychiatry. Am J Psychiatry (1977) 0.92
Coding SNPs included in exon arrays for the study of psychiatric disorders. Mol Psychiatry (2008) 0.92
Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs. Biol Psychiatry (1998) 0.92
Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord (2001) 0.92
Salivary cortisol levels in socially phobic adolescent girls. Depress Anxiety (1999) 0.92
Separation induced changes in squirrel monkey hypothalamic-pituitary-adrenal physiology resemble aspects of hypercortisolism in humans. Psychoneuroendocrinology (1999) 0.91
Tranylcypromine: effects on norepinephrine metabolism in rat brain. Am J Psychiatry (1970) 0.91
SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. J Sleep Res (2001) 0.91
Postnatal foraging demands alter adrenocortical activity and psychosocial development. Dev Psychobiol (1998) 0.91
Early environmental regulation of glucocorticoid feedback sensitivity in young adult monkeys. J Neuroendocrinol (2000) 0.91
Norepinephrine metabolism and drugs used in the affective disorders: a possible mechanism of action. Am J Psychiatry (1967) 0.91
The use of ECT in the treatment of schizophrenia. Am J Psychiatry (1980) 0.90
Psychological effects of tetrahydrocannabinol. Arch Gen Psychiatry (1970) 0.90
Value of the ring-enhancing sign in differentiating intracerebral hematomas and brain abscesses. Arch Intern Med (1987) 0.90
Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology (1988) 0.89
Cognitive-behavioral group therapy for social phobia in female adolescents: results of a pilot study. J Am Acad Child Adolesc Psychiatry (2000) 0.89
Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry (1984) 0.89
Neuropharmacology of the affective disorders. Annu Rev Pharmacol (1973) 0.89
The effects of a single acute dose of dexamethasone on monoamine and metabolite levels in rat brain. Life Sci (1985) 0.89
Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study. J Clin Psychopharmacol (1985) 0.89
Modelling the decline pattern in functional measures from a prevalent cohort study. Stat Med (2000) 0.89
Desynchronized sleep and MHPG excretion: an inverse correlation. Brain Res (1973) 0.88
High rate of affective disorders in probands with attention deficit disorder and in their relatives: a controlled family study. Am J Psychiatry (1987) 0.88
Abnormal results of dexamethasone suppression tests in nondepressed patients with diabetes mellitus. Arch Gen Psychiatry (1984) 0.88
Pharmacotherapy of depression and mixed states in bipolar disorder. J Affect Disord (2000) 0.87